These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31203104)

  • 1. The upregulation of Pim kinases is essential in coordinating the survival, proliferation, and migration of KIT D816V-mutated neoplastic mast cells.
    Park H; Kim D; Koh Y; Yoon SS
    Leuk Res; 2019 Aug; 83():106166. PubMed ID: 31203104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
    Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
    Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
    Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
    Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis.
    Haenisch B; Herms S; Molderings GJ
    Immunol Res; 2013 May; 56(1):155-62. PubMed ID: 23504229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.
    Gabillot-Carré M; Lepelletier Y; Humbert M; de Sepuvelda P; Hamouda NB; Zappulla JP; Liblau R; Ribadeau-Dumas A; Machavoine F; Letard S; Baude C; Hermant A; Yang Y; Vargaftig J; Bodemer C; Morelon E; Lortholary O; Recher C; Laurent G; Dy M; Arock M; Dubreuil P; Hermine O
    Blood; 2006 Aug; 108(3):1065-72. PubMed ID: 16597595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
    Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
    Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
    Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
    Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Prats-Martín C; Jiménez-Guerrero P; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; Pérez O; Montero I; Falantes J; Burillo-Sanz S; Carrillo E; Borrero JJ; Bernal R; Pérez-Simón JA
    Ann Hematol; 2018 Mar; 97(3):533-535. PubMed ID: 29151134
    [No Abstract]   [Full Text] [Related]  

  • 13. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
    Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
    Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
    Harir N; Boudot C; Friedbichler K; Sonneck K; Kondo R; Martin-Lannerée S; Kenner L; Kerenyi M; Yahiaoui S; Gouilleux-Gruart V; Gondry J; Bénit L; Dusanter-Fourt I; Lassoued K; Valent P; Moriggl R; Gouilleux F
    Blood; 2008 Sep; 112(6):2463-73. PubMed ID: 18579792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
    Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
    Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.